News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Musella Foundation awards research grant for promising new brain tumor therapy

Al's Comment:

 This is an exciting new treatment. It is a next generation combination targeting 2 pathways:

1. an antiangiogenic drug - which blocks the formation of new blood vessels, which starves the tumor

2. Anti-invasion - so the tumor cells can't spread out looking for a new blood supply.

 


Posted on: 09/13/2013

The Musella Foundation For Brain Tumor Research & Information, Inc has awarded a $30,000 research grant for the project titled:

Anti-Cancer Activity of OKN-007 in Pediatric Gliomas.  This is an experimental treatment that stops 2 growth mechanisms:  it stops the formation of new blood vessels, and it also stops invasion.  Earlier work on an adult glioblastoma rat model looked very good so a human recurrent adult high grade glioma trial has started.  Our project will pay for the pre-clinical work using this new drug on a pediatric glioma rat model, to pave the way for a pediatric brain tumor trial! There are more details about the treatment at:

http://newsok.com/omrf-researchers-finding-some-hope-in-anti-brain-tumor-drug/article/3809147

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740